A composition comprising a hydrogen peroxide source and at least one salicylate. Preferably, the hydrogen peroxide source comprises hydrogen peroxide and a means for generating hydrogen peroxide.

A topical treatment for anorectal disorders with and without utilization of a contoured seat cushion with a temperature-adapted or electrical stimulation element that can provide hot or cold temperatures or electrical stimulation to the anorectal region.

The present disclosure relates to novel topical formulations containing a tofacitinib and or a fingolimod that are useful for treating dermatological conditions, such as atopic dermatitis, psoriasis, and eczema.

Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided.

A stable and safe skin antiseptic solution comprises chlorhexidine, pharmaceutically acceptable salts of chlorhexidine (e.g. chlorhexidine digluconate), or a mixture thereof, dimethyl lauramide/myristamide, and water. Said solution is essentially free of coconut oil diethanolamine concentrate (“cocamide DEA”), a known carcinogen. The active antiseptic ingredient, chlorhexidine (or its salts), is a di(4-chlorophenyldiguanido) compound. The functions of dimethyl lauramide/myristamide in said solution include, but not limited to, an aesthetics enhancer, a foam stabilizer, a solubilizer, and a fragrance. Said solution is specifically formulated to be safe with a reduced risk of carcinogenicity, and be capable of producing a stable and long lasting foam. The active antiseptic agent is evenly distributed in said solution and in said foam, respectively.

The present invention relates to a device and method for making sclerosing foam, which is useful in the treatment of varicose veins and other venous conditions. The device comprises a continuous pathway that is at least partly formed of flexible or compressible material and that comprises a foam generating structure within the continuous pathway; the foam generating structure being formed of two or more elements, wherein each element defines at least one passageway of cross sectional area 1 μm2 to 10 mm2 and said two or more elements being arranged in series; a port which allows introduction of material into or extraction of material out of the continuous pathway; and a liquid pathway that is at least partly formed of flexible or compressible material and is arranged to deliver liquid into the foam generating structure between a first and second element of the foam generating structure.

The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and/or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.

The present disclosure relates to, inter alia, a formulation in a package, the formulation comprises one or more active agents and is co-mingled with a whipping agent prior to being filled under pressure into the package. The whipping agent is added in sufficient amounts to be dispersed in the formulation. The pressurized package is under sufficient pressure suitable to maintain the whipping agent dispersed in the formulation; and the pressurized package is under sufficient pressure to expel the formulation as a whipped formulation upon application of external force on the formulation in the package.

A foam inhalation device (874) for dispensing a foam to be inhaled by a user. The inhalation device (874) comprises a foam-generating component for generating the foam, an outlet (882) for dispensing the foam to the user, and a fluid flow path which fluidly communicates the foam-generating component with the outlet (882). The foam is generatable by the foam-generating component and flows to the outlet (882) via the fluid flow path to be inhaled by the user.

The present invention relates to an improved wound product that is equivocal to manuka honey in antimicrobial and wound healing effectiveness, but may be mixed with a therapeutic anesthetic, may have a fragrance, may be stored in a spray dispenser, may be used with a straw, and is applied as a foam. This provides the option of a straw being attached to the dispenser hole for dispensing honey foam for deep tunneling wound. It may also be sprayed directly on the wound or burn, or be sprayed on a sterile sponge for application.